{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-086170","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.309343+00:00","generated_at":"2026-05-19T08:31:24.899440+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Prelude Therapeutics appoints new director from Baker Bros.; shareholders approve increase in authorized shares","bullets":["Appointed Paul Scherer, M.D. (Baker Bros. Advisors) as Class III director; granted options for 76,000 shares vesting over one year.","Stockholders elected Martin Babler and Victor Sandor as Class II directors for three-year terms at 2025 annual meeting.","Ratified Ernst & Young as independent auditor for fiscal year 2025 with 32,364,505 votes for, 132,459 against.","Approved amendment increasing authorized non-voting common stock from 12,850,259 to 112,850,259 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-086170","json":"https://secwatch.observer/filing/0000950170-25-086170.json","markdown":"https://secwatch.observer/filing/0000950170-25-086170.md","text":"https://secwatch.observer/filing/0000950170-25-086170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025086170/0000950170-25-086170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025086170/prld-20250611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T08:31:24.899440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1f4089888","claim":"Paul Scherer was appointed as Class III Director at Prelude Therapeutics Inc.","evidence_excerpt":"the Board appointed Paul Scherer, M.D., as a Class III director and as a member of the Compensation committee and the Governance Committee of the Board, effective as of the adjournment of the 2025 Annual Meeting of Stockholders (the “ Annual Meeting ”) on June 12, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025086170/0000950170-25-086170-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}